Qβ VLPs

**Qβ VLPs** are virus-like particles derived from the bacteriophage Qβ, composed of 180 copies of a single viral coat protein that self-assemble into highly repetitive structures. These non-infectious particles can be chemically conjugated to display a variety of small molecules, peptides, or antigens on their surface at high density. Used as a vaccine platform, Qβ VLPs induce robust, long-lasting, and high-avidity antibody responses, often requiring few immunizations. They are highly thermostable and compatible with GMP manufacturing. Mechanistically, immunogenicity is driven by both the repetitive particle architecture and endogenous encapsidated RNA that acts as a TLR ligand (TLR7/8). Qβ VLPs have supported multiple applications as carrier platforms for vaccines targeting opioids (including oxycodone, heroin, fentanyl), infectious diseases, and cancers. They are under investigation both as stand-alone vaccines (e.g., anti-melanoma immunotherapy CMP-001) and as vaccines conjugated to specific antigenic haptens for disease-specific use[1][2][3][6].

Brand names

Qβ VLPs

Other names

Qbeta virus-like particlesQβ bacteriophage VLPsQβ VLP platform